New hope for kidney patients with Hard-to-Match immune systems

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and females age 18-70 years * End Stage Renal Disease (ESRD) on dialysis * Patient listed and active for a deceased donor kidney transplant and have not received compatible donor offer for ≥3 year. * Calculated PRA ≥ 99% * Positive CMV serology * Positive EBV serology * Current vaccination for more than one month for diphtheria, tetanus, poliomyelitis, influenza, pneumococcus, meningococcus, herpes zoster and SARS CoV-2. * Patient affiliated to social security insurance or beneficiary of social security insurance Exclusion Criteria: * Inability or unwillingness of a participant to give written informed consent or comply with study protocol * Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including HIV, hepatitis B, hepatitis C, zoster) * Patient with positive hepatitis core antigen and/or positive hepatitis B surface antigen * Serious uncontrolled concomitant major organ disease * Any infection requiring hospitalization and intravenous antibiotics within 4 weeks of screening or Per os antibiotics within 2 weeks * Primary or secondary immunodeficiency * History of active tuberculosis (TB) (even if treated) or untreated latent TB * Malignancy within the last 5 years except documented and treated basal and squamous cell cancer of the skin * Alcohol, drug or chemical abuse within 1 year * Difficult peripheral venous access * Negative EBV serology * Negative CMV serology * Neutropenia (ANC \<1000/uL) or thrombocytopenia (platelet count \<100,000/uL) within 4 weeks prior to study entry * Patient previously treated with investigational products (belatacept, daratumumab) * Severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies * Hypersensitivity to any active substance or component of the investigational medicinal products * Any contra-indication to premedication drugs (paracetamol, dexchlorpheniramine, cetirizine, dexamethasone, montelukast) or post-medication drugs (corticosteroids, bronchodilators, valaciclovir) * Immunization with live vaccine within 2 months of study entry * Dry body weight ≥75kg. * Pregnancy or lactation * Females with childbearing status, defined as a premenopausal female capable of becoming pregnant, and not using an effective form of birth control. Effective birth control methods include oral, implant or patch hormone contraception; intrauterine device; abstinence and outercourse; tubal ligation; vasectomy. * Participant involved in another interventional clinical study * Person deprived of liberty by judicial order * Person under guardianship or curatorship